Takeda: Duodenal Ulcer trials

The registry lists 17 Duodenal Ulcer studies with Takeda as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 3 10No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"CompletedNCT03219723Results posted
• Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"CompletedNCT03214952Results posted
• Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"CompletedNCT03214198Results posted
• Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"CompletedNCT03214094Results posted
• Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori InfectionCompletedNCT03050359Phase 3Results posted
• Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]CompletedNCT02151786Results posted
• Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory DrugsCompletedNCT02099708Results posted
• Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose AspirinCompletedNCT02099682Results posted
• Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory DrugsCompletedNCT00787254Phase 3Results posted
• A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal UlcersTerminatedNCT00762359Phase 3Results posted
• A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin TherapyCompletedNCT01568398Phase 3
• A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) TherapyCompletedNCT01568385Phase 3
• Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNCT01456260Phase 3
• Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNCT01456247Phase 3
• Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNCT01452763Phase 3
• Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNCT01452750Phase 3
• Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerCompletedNCT01452724Phase 3